ProKidney Corp Ownership
| PROK Stock | USD 1.85 0.03 1.60% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
ProKidney |
ProKidney Stock Ownership Analysis
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.54. ProKidney Corp had not issued any dividends in recent years. The entity had 1:1 split on the 12th of July 2022. ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about ProKidney Corp contact Bruce MD at 336 999 7028 or learn more at https://www.prokidney.com.Besides selling stocks to institutional investors, ProKidney Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ProKidney Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ProKidney Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ProKidney Corp Quarterly Liabilities And Stockholders Equity |
|
About 27.0% of ProKidney Corp are currently held by insiders. Unlike ProKidney Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ProKidney Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ProKidney Corp's insider trades
ProKidney Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProKidney Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProKidney Corp backward and forwards among themselves. ProKidney Corp's institutional investor refers to the entity that pools money to purchase ProKidney Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 288 K | Bank Of New York Mellon Corp | 2024-06-30 | 179.2 K | Alps Advisors Inc | 2024-09-30 | 97.4 K | Millennium Management Llc | 2024-06-30 | 91.9 K | Alliancebernstein L.p. | 2024-06-30 | 84.2 K | Rhumbline Advisers | 2024-06-30 | 76.2 K | Citigroup Inc | 2024-09-30 | 75.2 K | Metlife Investment Management, Llc | 2024-09-30 | 62.7 K | Mariner Wealth Advisors Llc | 2024-06-30 | 51.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 28.9 M | Suvretta Capital Management, Llc | 2024-06-30 | 9.3 M |
ProKidney Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProKidney Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProKidney Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProKidney Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.